Molecular Cancer Therapeutics

• 

  Publication Venue For

  • Preclinical Testing of a Novel Niclosamide Stearate Prodrug Therapeutic (NSPT) Shows Efficacy Against Osteosarcoma..  19:1448-1461. 2020
  • Abstract B38: p90RSK mediates resistance to PI3K-pathway inhibitors in breast cancer.  14:B38-B38. 2015
  • Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer..  14:920-930. 2015
  • Inhibition of endoglin-GIPC interaction inhibits pancreatic cancer cell growth..  13:2264-2275. 2014
  • Abstract B151: Monitoring tumor microenvironment (Hb saturation and oxygenation) in response to plasmonics-assisted photothermal cancer therapy..  12:B151-B151. 2013
  • Abstract C248: Novel PORCN inhibitors are safe and effective in the treatment of WNT-dependent cancers..  12:C248-C248. 2013
  • Abstract C61: Phase I Study of pazopanib in combination with the investigational hypoxia-targeted drug TH-302..  12:C61-C61. 2013
  • Abstract C85: Drug interaction study of tivantinib in cancer subjects using a cocktail approach..  12:C85-C85. 2013
  • Abstract A18: Genetic elements of cancer cell survival in tumor microenvironment stresses.  12:A18-A18. 2013
  • Activity of a Py-Im polyamide targeted to the estrogen response element..  12:675-684. 2013
  • Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression..  8:533-542. 2009
  • A peptide inhibitor derived from p55PIK phosphatidylinositol 3-kinase regulatory subunit: a novel cancer therapy..  7:3719-3728. 2008
  • A genomic approach to identify molecular pathways associated with chemotherapy resistance..  7:3141-3149. 2008
  • N-(4-Hydroxyphenyl)retinamide increases dihydroceramide and synergizes with dimethylsphingosine to enhance cancer cell killing..  7:2967-2976. 2008
  • Relaxin treatment of solid tumors: effects on electric field-mediated gene delivery..  7:2566-2573. 2008
  • The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor-induced apoptosis..  7:2212-2223. 2008
  • ISG15 as a novel tumor biomarker for drug sensitivity..  7:1430-1439. 2008
  • The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis..  7:1251-1257. 2008
  • LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis..  7:829-840. 2008
  • Differential effects of prostate cancer therapeutics on neuroendocrine transdifferentiation..  7:659-669. 2008
  • Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression..  7:38-47. 2008
  • Pediatric preclinical testing program (PPTP) evaluation of the EGFR and ErbB2 inhibitor lapatinib.  6:3471S-3471S. 2007
  • Pediatric preclinical testing program (PPTP) evaluation of the fully human anti-IGF-1R antibody SCH 717454.  6:3405S-3405S. 2007
  • Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen..  6:2817-2827. 2007
  • The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion..  6:2449-2457. 2007
  • Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice..  6:2280-2289. 2007
  • Suppression of RelB-mediated manganese superoxide dismutase expression reveals a primary mechanism for radiosensitization effect of 1alpha,25-dihydroxyvitamin D(3) in prostate cancer cells..  6:2048-2056. 2007
  • Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents..  6:1492-1500. 2007
  • In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1..  6:450-459. 2007
  • A phase I trial of hyperthermia-induced interleukin-12 gene therapy in spontaneously arising feline soft tissue sarcomas..  6:380-389. 2007
  • Mutation analysis of 24 known cancer genes in the NCI-60 cell line set..  5:2606-2612. 2006
  • Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma..  5:2531-2539. 2006
  • Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells..  5:2251-2260. 2006
  • Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth..  5:1079-1086. 2006
  • Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine..  5:732-738. 2006
  • Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt..  5:713-722. 2006
  • Effects of rate, volume, and dose of intratumoral infusion on virus dissemination in local gene delivery..  5:362-366. 2006
  • Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity..  5:356-361. 2006
  • Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft..  4:1364-1368. 2005
  • Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival..  4:257-270. 2005
  • Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition..  4:101-112. 2005
  • Targeting tumor microvessels using doxorubicin encapsulated in a novel thermosensitive liposome..  3:1311-1317. 2004
  • Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations..  3:1127-1135. 2004
  • In vitro evaluation of dimethane sulfonate analogues with potential alkylating activity and selective renal cell carcinoma cytotoxicity..  3:849-860. 2004
  • SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility..  3:737-745. 2004
  • X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells..  3:699-707. 2004
  • Systemic dissemination of viral vectors during intratumoral injection..  2:1233-1242. 2003
  • Characterization of the cytotoxic activities of novel analogues of the antitumor agent, lavendamycin..  2:517-526. 2003
  • Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts..  1:1243-1253. 2002
  • O6-benzylguanine-mediated enhancement of chemotherapy..  1:943-948. 2002
  • Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells..  1:707-717. 2002
  • Mechanisms of resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea in human medulloblastoma and rhabdomyosarcoma..  1:727-736. 2002
  • Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I..  1:747-758. 2002
  • Dual role of glutathione in modulating camptothecin activity: depletion potentiates activity, but conjugation enhances the stability of the topoisomerase I-DNA cleavage complex..  1:11-20. 2001
  • Effect of O6-benzylguanine on nitrogen mustard-induced toxicity, apoptosis, and mutagenicity in Chinese hamster ovary cells..  1:21-28. 2001
  • Vertical Inhibition of the RAF-MEK-ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRAS^Q61X Mutant Rhabdomyosarcoma. 2022
  • Abstract A074: Correlation of homologous recombination deficiency (HRD) status by BROCA-HR sequencing with response to combination cediranib and olaparib in relapsed ovarian cancer 2019
  • Abstract B166: Investigating the effect of CDK4/6 and MDM2 inhibition on melanoma 2018
  • Abstract CN02-02: Immunotherapy for central nervous system cancers 2018
  • Abstract A03: Several rational combination kinase inhibitor treatments identified by synthetic lethality screens are efficacious in intracranial triple negative breast cancer models 2017
  • Abstract PR18: Leveraging synthetic lethality to target convergent therapeutic resistance 2017
  • Abstract C263: mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. 2013
  • Abstract C86: Tethered Hsp90 inhibitors carrying optical or radioiodinated probes reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells. 2013
  • Abstract A10: Antiangiogenic therapy (VEGF-R1–3 and PDGFR inhibitor) increases tumor hemoglobin saturation and decreases interstitial pressure, and microvessel density 2009
  • Abstract A7: Targeting the tumor microenvironment via inhibition of VEGF and PDGF to improve liposomal drug delivery in human non-small cell lung cancer xenografts 2009
  • Abstract B264: IC261 induces cell cycle arrest and apoptosis of human cancer cells via a CK1δ/ε independent mechanism 2009
  • Pancreatic cancer targeted C-VISA-BikDD: DNA-liposome complex results in minimal toxicity in vivo 2007